96 related articles for article (PubMed ID: 17395409)
1. Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Sismondi P; Biglia N; Ponzone R; Fuso L; Scafoglio C; Cicatiello L; Ravo M; Weisz A; Cimino D; Altobelli G; Friard O; De Bortoli M
Maturitas; 2007 May; 57(1):50-5. PubMed ID: 17395409
[TBL] [Abstract][Full Text] [Related]
2. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
3. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells.
Wang Z; Kyo S; Maida Y; Takakura M; Tanaka M; Yatabe N; Kanaya T; Nakamura M; Koike K; Hisamoto K; Ohmichi M; Inoue M
Oncogene; 2002 May; 21(22):3517-24. PubMed ID: 12032853
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
6. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Pole JC; Gold LI; Orton T; Huby R; Carmichael PL
Toxicology; 2005 Jan; 206(1):91-109. PubMed ID: 15590111
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
[TBL] [Abstract][Full Text] [Related]
9. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells.
Scafoglio C; Ambrosino C; Cicatiello L; Altucci L; Ardovino M; Bontempo P; Medici N; Molinari AM; Nebbioso A; Facchiano A; Calogero RA; Elkon R; Menini N; Ponzone R; Biglia N; Sismondi P; De Bortoli M; Weisz A
J Cell Biochem; 2006 Aug; 98(5):1163-84. PubMed ID: 16514628
[TBL] [Abstract][Full Text] [Related]
10. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
11. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
12. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
[TBL] [Abstract][Full Text] [Related]
13. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.
Diel P; Olff S; Schmidt S; Michna H
Planta Med; 2001 Aug; 67(6):510-4. PubMed ID: 11509969
[TBL] [Abstract][Full Text] [Related]
14. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulators prevent neointima formation after vascular injury.
Savolainen-Peltonen H; Luoto NM; Kangas L; Häyry P
Mol Cell Endocrinol; 2004 Nov; 227(1-2):9-20. PubMed ID: 15501580
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
Suuronen T; Nuutinen T; Huuskonen J; Ojala J; Thornell A; Salminen A
Inflamm Res; 2005 May; 54(5):194-203. PubMed ID: 15953991
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and ZK 119010 exert mixed agonistic and antagonistic effects on pS2 expression in MCF-7 cells.
Schütze N; Schneider MR; Knuppen R; Vollmer G
Cancer Detect Prev; 1994; 18(6):479-83. PubMed ID: 7867021
[TBL] [Abstract][Full Text] [Related]
19. Comparative analyses of mechanistic differences among antiestrogens.
Wijayaratne AL; Nagel SC; Paige LA; Christensen DJ; Norris JD; Fowlkes DM; McDonnell DP
Endocrinology; 1999 Dec; 140(12):5828-40. PubMed ID: 10579349
[TBL] [Abstract][Full Text] [Related]
20. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
Glaeser M; Niederacher D; Djahansouzi S; Hanstein B; Dittrich R; Beckmann MW; Fasching PA; Ackermann S
Anticancer Res; 2006; 26(1B):735-44. PubMed ID: 16739346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
